Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: A tissue microarray and pooled literature review study

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 5, 2009, Pages 393-402

  Wei, Shi ^a   Said Al Naief, Nasser ^a   Hameed, Omar ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Carcinoma; Estrogen receptor; Immunohistochemistry; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BLADDER TUMOR; BREAST CARCINOMA; COLORECTAL TUMOR; ESOPHAGUS TUMOR; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; LUNG CARCINOMA; LUNG TUMOR; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH TUMOR; TISSUE MICROARRAY; TUMOR DIAGNOSIS;

BREAST NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY;

EID: 70349728696     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31819faa07     Document Type: Article

References (84)

1. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of The Breast and Female Genital Organs. Lyon: IARC Press; 2003:432.
2. NCCN. Clinical Practice Guidelines in Oncology: Occult Primary. V.1.2009 ed. Fort Washington, PA: National Comprehensive Cancer Network; 2008.
3. Bugat R, Bataillard A, Lesimple T, et al. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003; 89(suppl 1):S59-S66.
4. Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol. 1998;29:1393-1402. (Pubitemid 28563971)
5. Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med. 2008; 132:326-348. (Pubitemid 351328809)
6. Burford HN, Adams AL, Hameed O. Effect of storage on p63 immunohistochemistry: a time-course study. Appl Immunohistochem Mol Morphol. 2009;17:68-71.
7. Canver CC, Memoli VA, Vanderveer PL, et al. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg. 1994;108:153-157.
8. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res. 1996;16:3803-3806. (Pubitemid 27085052)
9. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med. 1994;118:630-632.
10. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer. 1996;67:357-364. (Pubitemid 26274126)
11. Kaufmann O, Kother S, Dietel M. Use of antibodies against estrogen and progesterone receptors to identify metastatic breast and ovarian carcinomas by conventional immunohistochemical and tyramide signal amplification methods. Mod Pathol. 1998;11: 357-363. (Pubitemid 28208097)
12. Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology. 1996;29:233-240. (Pubitemid 26302731)
13. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
14. Vargas SO, Leslie KO, Vacek PM, et al. Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma: pathologic and prognostic correlations. Cancer. 1998;82:1495-1500.
15. Di Nunno L, Larsson LG, Rinehart JJ, et al. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med. 2000;124:1467-1470. (Pubitemid 30802495)
16. Omoto Y, Kobayashi Y, Nishida K, et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun. 2001;285:340-347. (Pubitemid 32918076)
17. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg. 2002;73:403-405. (Pubitemid 34117378)
18. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2002;8:69-73.
19. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol. 2006;14:83-87.
20. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
21. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.
22. Uehara Y, Takahashi T, Kojima O, et al. Peroxidase-antiperoxidase staining for estrogen and progesterone in scirrhous type of gastric cancer: possible existence of the estrogen receptor. Jpn J Surg. 1986;16:245-249. (Pubitemid 17171837)
23. Zhao XH, Gu SZ, Liu SX, et al. Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues. World J Gastroenterol. 2003;9:665-669. (Pubitemid 36531535)
24. Tiffin N, Suvarna SK, Trudgill NJ, et al. Sex hormone receptor immunohistochemistry staining in Barrett's oesophagus and adenocarcinoma. Histopathology. 2003;42:95-96. (Pubitemid 36062576)
25. Chu PG, Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol. 2004;121:884-892. (Pubitemid 38669284)
26. Yokozaki H, Takekura N, Takanashi A, et al. Estrogen receptors in gastric adenocarcinoma: a retrospective immunohistochemical analysis. Virchows Arch A Pathol Anat Histopathol. 1988;413: 297-302. (Pubitemid 18207784)
27. Kojima O, Takahashi T, Kawakami S, et al. Localization of estrogen receptors in gastric cancer using immunohistochemical staining of monoclonal antibody. Cancer. 1991;67:2401-2406.
28. Matsui M, Kojima O, Kawakami S, et al. The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today. 1992;22:421-425.
29. Cameron BL, Butler JA, Rutgers J, et al. Immunohistochemical determination of the estrogen receptor content of gastrointestinal adenocarcinomas. Am Surg. 1992;58:758-760. (Pubitemid 23004442)
30. Koullias GJ, Kouraklis GP, Raftopoulos IS, et al. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. J Surg Oncol. 1996;63:166-171.
31. Machado JC, Carneiro F, Gartner F, et al. Female sex hormone receptors are not involved in gastric carcinogenesis. A biochemical and immunohistochemical study. Eur J Cancer Prev. 1994;3(suppl 2): 31-37.
32. Chaubert P, Bouzourene H, Saraga E. Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population. Mod Pathol. 1996;9:189-193. (Pubitemid 26126542)
33. Matsuyama S, Ohkura Y, Eguchi H, et al. Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol. 2002;128:319-324. (Pubitemid 34569353)
34. O'Connell FP, Wang HH, Odze RD. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005;129:338-347.
35. Van Velthuysen ML, Taal BG, Van der Hoeven JJ, et al. Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology. 2005;46: 153-157.
36. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006;19:97-105. (Pubitemid 43250984)
37. Targarona EM, Pons MD, Gonzalez G, et al. Is exocrine pancreatic cancer a hormone-dependent tumor? A study of the existence of sex hormone receptors in normal and neoplastic pancreas. Hepatogastroenterology. 1991;38:165-169.
38. Singh S, Baker PR, Poulsom R, et al. Expression of oestrogen receptor and oestrogen-inducible genes in pancreatic cancer. Br J Surg. 1997;84:1085-1089. (Pubitemid 27359479)
39. Yeh TS, Jan YY, Chiu CT, et al. Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Gut. 2002;51:712-716.
40. Singh S, Poulsom R, Hanby AM, et al. Expression of oestrogen receptor and oestrogen-inducible genes pS2 and ERD5 in large bowel mucosa and cancer. J Pathol. 1998;184:153-160. (Pubitemid 28088423)
41. Dionigi A, Facco C, Tibiletti MG, et al. Ovarian metastases from colorectal carcinoma. Clinicopathologic profile, immunophenotype, and karyotype analysis. Am J Clin Pathol. 2000;114:111-122. (Pubitemid 34453192)
42. Goldstein NS, Long A, Kuan SF, et al. Colon signet ring cell adenocarcinoma: immunohistochemical characterization and comparison with gastric and typical colon adenocarcinomas. Appl Immunohistochem Mol Morphol. 2000;8:183-188. (Pubitemid 30677903)
43. Slattery ML, Samowitz WS, Holden JA. Estrogen and progesterone receptors in colon tumors. Am J Clin Pathol. 2000;113:364-368. (Pubitemid 30217383)
44. Brown DF, Dababo MA, Hladik CL, et al. Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas. Mod Pathol. 1998;11:55-59. (Pubitemid 28177364)
45. Nolan LP, Heatley MK. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol. 2001;20:155-159. (Pubitemid 32239207)
46. Cameron RI, Ashe P, O'Rourke DM, et al. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2003;22:272-276. (Pubitemid 36750410)
47. Langner C, Ratschek M, Rehak P, et al. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol. 2004;171:611-614. (Pubitemid 38090441)
48. Bodker A, Balslev E, Juul BR, et al. Estrogen receptors in the human male bladder, prostatic urethra, and prostate. An immunohistochemical and biochemical study. Scand J Urol Nephrol. 1995;29:161-165.
49. Basakci A, Kirkali Z, Tuzel E, et al. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol. 2002;41:342-345. (Pubitemid 35303436)
50. Kaufmann O, Baume H, Dietel M. Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique. J Pathol. 1998;186:165-168. (Pubitemid 28467826)
51. Croft PR, Lathrop SL, Feddersen RM, et al. Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma. Arch Pathol Lab Med. 2005; 129:194-199. (Pubitemid 40204797)
52. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-alpha and beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006;106:2610-2616. (Pubitemid 43911828)
53. Pacchioni D, Revelli A, Casetta G, et al. Immunohistochemical detection of estrogen and progesterone receptors in the normal urinary bladder and in pseudomembranous trigonitis. J Endocrinol Invest. 1992;15:719-725. (Pubitemid 23052485)
54. Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int. 2000;86:32-38. (Pubitemid 30420760)
55. Celayir S, Ilce Z, Dervisoglu S. The sex hormone receptors in the bladder in childhood-I: preliminary report in male subjects. Eur J Pediatr Surg. 2002;12:312-317. (Pubitemid 35434697)
56. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257-263. (Pubitemid 23203818)
57. Armstrong AC, Blackhall FH. Management of cancer from an unknown primary. Expert Opin Pharmacother. 2007;8:445-455.
58. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561-570.
59. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol. 2005;12:10-19. (Pubitemid 40614485)
60. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978;5: 428-433.
61. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721-7735. (Pubitemid 46291836)
62. Kanai M, Shiozawa T, Xin L, et al. Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix. Cancer. 1998;82:1709-1719. (Pubitemid 28208922)
63. Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol. 2001;20:64-78.
64. Peluso JJ. Non-genomic actions of progesterone in the normal and neoplastic mammalian ovary. Semin Reprod Med. 2007;25:198-207.
65. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005. (Pubitemid 37297755)
66. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785. (Pubitemid 38529553)
67. Dabbs DJ. Diagnostic Immunohistochemistry. 2nd ed. Edinburgh: Churchill Livingstone Elsevier; 2006:xv, 828.
68. Park SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 2007;131:1561-1567.
69. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer. 2002;38:758-763. (Pubitemid 34280319)
70. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008;132:384-396. (Pubitemid 351328813)
71. Striebel JM, Dacic S, Yousem SA. Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol. 2008;32:426-432.
72. Takeda Y, Tsuta K, Shibuki Y, et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med. 2008;132:239-243. (Pubitemid 351213793)
73. Sasaki E, Tsunoda N, Hatanaka Y, et al. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol. 2007;20:208-214. (Pubitemid 46422175)
74. Vassallo J, Pinto GA, Alvarenga JM, et al. Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morphol. 2004; 12:177-182. (Pubitemid 38796461)
75. Bevitt DJ, Milton ID, Piggot N, et al. New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J Pathol. 1997;183:228-232. (Pubitemid 27436029)
76. Kaplan PA, Frazier SR, Loy TS, et al. 1D5 and 6F11: An immunohistochemical comparison of two monoclonal antibodies for the evaluation of estrogen receptor status in primary breast carcinoma. Am J Clin Pathol. 2005;123:276-280.
77. Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127:1591-1595. (Pubitemid 37517470)
78. Press M, Spaulding B, Groshen S, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 2002;67:799-813. (Pubitemid 34765669)
79. Rocha R, Nunes C, Rocha G, et al. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. Pathol Res Pract. 2008;204:655-662.
80. Huang Z, Zhu W, Meng Y, et al. Development of new rabbit monoclonal antibody to progesterone receptor (Clone SP2): no heat pretreatment but effective for paraffin section immunohistochemistry. Appl Immunohistochem Mol Morphol. 2006;14: 229-233.
81. Ibrahim M, Dodson A, Barnett S, et al. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol. 2008;129: 398-409. (Pubitemid 352029292)
82. Goldstein NS, Hewitt SM, Taylor CR, et al. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007;15:124-133.
83. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
84. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol. 1997;24: S165-S170.